Daily Respiratory Research Analysis
Analyzed 199 papers and selected 3 impactful papers.
Summary
Analyzed 199 papers and selected 3 impactful articles.
Selected Articles
1. Effect of Paroxetine or Escitalopram Co-administered with Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial.
In a double-blind, 3-period crossover RCT in healthy adults, 21-day paroxetine or escitalopram significantly reduced the hypercapnic ventilatory response, both alone and when co-administered with oxycodone. Mean ventilation decreased by 6–7 L/min versus placebo and by 5–6 L/min versus oxycodone alone, indicating an SSRI class effect that persists with chronic use.
Impact: Findings directly inform perioperative and pain management safety by identifying a consistent SSRI-associated depression of ventilatory drive, especially relevant when combined with opioids.
Clinical Implications: Clinicians should recognize chronic SSRI therapy as a risk factor for reduced ventilatory reserve under hypercapnic stress and heightened susceptibility to opioid-induced respiratory depression. Consider dose adjustments, enhanced monitoring, or opioid-sparing analgesia in SSRI users.
Key Findings
- Paroxetine and escitalopram each reduced hypercapnic ventilation versus placebo at day 20 by approximately 6.5–6.9 L/min.
- Co-administration with oxycodone further reduced ventilation versus oxycodone alone at day 21 by 5.5–6.5 L/min.
- Results support a class effect of SSRIs on blunting hypercapnic ventilatory response after 21 days of therapy.
Methodological Strengths
- Randomized, double-blind, 3-period crossover design minimizing inter-individual variability
- Objective physiologic outcome using Duffin’s hyperoxic-hypercapnic rebreathing protocol with repeated assessments
Limitations
- Small sample size (27 randomized; 22 completed) of healthy volunteers limits generalizability to patient populations
- Single opioid (oxycodone 10 mg) tested; effects with other opioids, sedatives, or comorbidities remain unknown
Future Directions: Evaluate SSRI–opioid interactions in clinical populations (e.g., chronic pain, perioperative patients, OSA), assess dose–response, pharmacogenomic modifiers, and effects with other respiratory depressants.
BACKGROUND: Opioid-induced respiratory depression remains a critical public safety concern. Prior clinical findings demonstrated decreased hypercapnic ventilation after 5 days when paroxetine, a Selective Serotonin Reuptake Inhibitor (SSRI), was administered alone or with oxycodone. However, uncertainty remained whether chronic use of SSRIs could cause similar respiratory effects. This study investigated whether chronic use of paroxetine and another SSRI, escitalopram, lead to a similar decrease in ventilatory response to hypercapnia. METHOD: In this randomized, double-blind, 3-period crossover trial, healthy participants were administered one of the following: paroxetine 40 mg from days 1 to 6 and 60 mg from days 7 to 21, escitalopram 20 mg from days 1 to 6 and 30 mg from days 7 to 21, and placebo from days 1 to 21. Oxycodone 10 mg was co-administered on days 6, 12, and 21. Hyperoxic-hypercapnic ventilation was measured using Duffin's rebreathing. RESULTS: Of the 27 participants, 22 (81%) completed the trial. Paroxetine and escitalopram both significantly decreased hyperoxic-hypercapnic ventilation when co-administered with oxycodone compared to oxycodone alone on day 21 (paroxetine mean difference, -6.5 L/min [1-sided 97.5% CI, -∞ to -3.1] P<0.001, escitalopram mean difference, -5.5 L/min [1-sided 97.5% CI, -∞ to -2.1] P=0.001) and when administered alone compared to placebo on day 20 (paroxetine mean difference, -6.5 L/min [1-sided 97.5% CI, -∞ to -2.1] P=0.003, escitalopram mean difference, -6.9 L/min [1-sided 97.5% CI, -∞ to -2.5] P=0.002). CONCLUSIONS: Both paroxetine and escitalopram, alone and co-administered with oxycodone, decrease hypercapnic ventilation after 21 days suggesting that selective serotonin reuptake inhibitors may have a class effect on hypercapnic ventilation that persists with chronic use.
2. Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities.
Using 82 fresh EBUS-TBNA aspirates, methylation profiling defined four SCLC subgroups with distinct survival and tumor-intrinsic/extrinsic features. Therapeutic targets (e.g., DLL3 in SCLC-A, TACSTD2 in non-NE group 4, and broadly expressed SEZ6) emerged, demonstrating that minimally invasive samples can support clinically actionable stratification.
Impact: This study operationalizes multi-omics on routine needle aspirates to stratify SCLC with clear survival differences and targetable vulnerabilities, bridging laboratory insights and clinical decision-making.
Clinical Implications: Methylation-based subtyping from EBUS-TBNA can inform trial design and therapeutic choices (e.g., DLL3- or TACSTD2-directed agents), and identify immune-enriched subsets likely to benefit from immunotherapy.
Key Findings
- Methylation profiling of 82 EBUS-TBNA SCLC samples defined four subgroups with distinct survival and tumor-intrinsic/extrinsic features.
- Group 1: ASCL1-high, immune-enriched neuroendocrine with higher CD8+ T cells and better survival.
- Group 2 (SCLC-A): ASCL1-high with high SLFN11 and DLL3 expression, suggesting sensitivity to DNA-damaging therapy and DLL3-targeted agents.
- Group 3 (SCLC-N): NEUROD1-high/hypomethylated with a higher proportion of fibroblasts.
- Group 4: POU2F3/YAP1, non-neuroendocrine phenotype, worst survival, elevated TACSTD2 as a therapeutic opportunity; SEZ6 broadly expressed across SCLC.
Methodological Strengths
- Integrated multi-omics on fresh clinical EBUS-TBNA aspirates (methylome, WGS, RNA-seq, cfDNA).
- Subgrouping aligned with survival and microenvironmental features, enhancing clinical interpretability.
Limitations
- Sub-analyses used smaller subsets (e.g., RNA-seq n=48), potentially limiting power.
- External validation and prospective interventional confirmation are needed.
Future Directions: Prospective validation across centers, integration with imaging/ctDNA for longitudinal monitoring, and biomarker-driven trials targeting DLL3, TACSTD2, and SEZ6 by subgroup.
BACKGROUND: Small cell lung cancer (SCLC) is an aggressive disease that is often diagnosed at an advanced stage when surgery is no longer feasible. The lack of tumor tissue and rapid clinical decline of patients have hindered the feasibility of large omics studies. However, with advances in omics technologies recent studies have started to unravel the molecular heterogeneity of SCLCs. METHODS: Here, 82 fresh EBUS-TBNA aspirates underwent methylation profiling (EPIC arrays), with subsets of those subjected to whole-genome sequencing (n = 76), RNA-seq (n = 48) and blood cfDNA sequencing (n = 69) to characterize the molecular features of SCLCs. RESULTS: Methylation profiling revealed four sub-groups associated with distinct survival and extrinsic/intrinsic tumor features. Groups 1 and 2 presented increased expression of ASCL1. Group 1 tumors had a greater proportion of CD8 + T cells (immune enriched-NE) and patients with better survival. Group 2 (SCLC-A) harbored the largest number of cases, and high expression of SLFN11 and DLL3, as potential therapeutic options. Group 3 tumors presented increased expression and hypomethylation of NEUROD1 (SCLC-N), with a greater proportion of fibroblasts. Group 4 tumors expressed POU2F3 and/or YAP1, had increased expression of non-neuroendocrine genes (non-NE) and had the worst survival. TACSTD2 expression was higher in Group 4, suggesting a potential therapeutic option for this group. SEZ6, another potential therapeutic option, was highly expressed in most SCLCs. These results highlight that novel therapeutic options may need to be considered in the context of SCLC heterogeneity. CONCLUSIONS: We showed that methylation of the most common source of tumor tissue in the clinical setting can stratify SCLCs with distinct clinical outcomes and potentially tailored therapeutic options. Methylation can characterize the intrinsic and extrinsic heterogeneity of SCLCs and fuel the discovery of novel therapeutic vulnerabilities to help bridge the gap between research and clinical application to improve care for SCLC patients.
3. 'Tripod-like' lung-targeting (LuT) lipids for highly efficient and selective LNPs for gene delivery and editing.
A 444-lipid screen identified tripod-like LuT lipids that form LNPs achieving >90% lung selectivity, 25.5-fold higher mRNA delivery, and 9.2-fold higher CRISPR-Cas9 editing versus benchmark DOTAP SORT. Lead 1A7B13 also delivered IL-10 mRNA therapeutically in acute lung injury, mapping structure–activity rules that enable lung-specific nucleic acid therapeutics.
Impact: Defines a generalizable design rule for lung-selective LNPs with large performance gains and demonstrates therapeutic payload delivery, opening a path to gene therapy/editing across pulmonary diseases.
Clinical Implications: If safety and durability are confirmed, these LuT LNPs could enable lung-specific gene therapies (e.g., CFTR repair, A1AT augmentation, antifibrotic or anti-inflammatory mRNA) with improved therapeutic index.
Key Findings
- Screened 444 LuT lipids and identified a tripod-like motif (quaternary amine head, three long alkyl chains, one short chain) as optimal for lung targeting.
- Lead 1A7B13 LNPs achieved >90% lung selectivity, 25.5-fold higher mRNA delivery, and 9.2-fold higher CRISPR-Cas9 editing versus DOTAP SORT LNPs.
- Mechanistic analyses showed improved endosomal escape, cargo release, and endogenous targeting via plasma protein adsorption.
- Therapeutic delivery of IL-10 mRNA improved outcomes in an acute lung injury model.
Methodological Strengths
- Large-scale structure–activity screen across 444 lipids with in vivo benchmarking against a recognized standard.
- Mechanistic evaluation (endosomal escape, protein corona-mediated targeting) linking chemistry to biological performance.
Limitations
- Preclinical models; long-term safety, immunogenicity, and repeat dosing in large animals/humans remain unknown.
- Manufacturability and delivery modalities (e.g., aerosolization) require optimization for clinical translation.
Future Directions: IND-enabling toxicology, aerosol delivery development, repeat-dosing studies, and disease-focused gene correction/editing (e.g., CFTR, SERPINA1) with pharmacodynamic biomarkers.
Developing lung-targeting delivery systems is essential for treating pulmonary conditions such as genetic respiratory diseases, infections, fibrosis and cancer. We synthesized and evaluated 444 lung-targeting lipids (LuT lipids) that form lipid nanoparticles (LNPs) to efficiently deliver messenger RNA and CRISPR-Cas9 genome editors to lungs with minimal side effects. Empirical analyses revealed structure-activity relationships, with top-performing LuT lipids possessing a unique 'tripod-like' structure consisting of a quaternary amine head, three long alkyl chains as legs and a short chain as a handle. LuT lipids improved endosomal escape, cargo release and endogenous targeting via adsorption of plasma proteins. Lead 1A7B13 LNPs showed a 25.5-fold improvement in mRNA delivery and a 9.2-fold increase in CRISPR-Cas9 gene-editing efficiency compared to benchmark DOTAP SORT LNPs, achieving over 90% selectivity to the lungs. 1A7B13 LNPs effectively delivered IL-10 mRNA in a therapeutic model of acute lung injury. This study reveals the relationship between lipid structure and lung-targeting activity, enriching the toolkit for lung-specific carriers.